News

Bonumose Announces Key Advisory and Leadership Appointments

Bonumose, Inc. – an enzyme technology company with solutions for sugar reduction and other globally critical industries – is pleased to announce the following appointments.

  • Dr. Andrew Fordyce has accepted a key advisory role with Bonumose. Dr. Fordyce most recently was Executive Vice President and Food & Beverage Divisional Head for Novozymes, a global leader in biological solutions. His experience includes executive management in both functional and business unit organizational structures and he has had a multifaceted career that has covered biotech innovation and business strategy, marketing and business portfolio management, and process engineering and application research. Over Dr. Fordyce’s 27-year career at Novozymes he served multiple management roles including 7 years on the Novozymes’ Executive Leadership Team. Dr. Fordyce is advising Bonumose on multiple aspects of the enzyme value chain, as well as general R&D and business matters.
  • Dr. Katie Whalen. Bonumose has appointed Dr. Whalen, Director of Innovation Delivery, to the additional role of Chief of Staff. Dr. Whalen has a PhD in Biochemistry and prior to Bonumose spent 5 years at Kalsec. In her expanded role, Dr. Whalen is Bonumose’s lead on identifying and filling gaps for organizational capacity development, and also is responsible for ensuring Bonumose maintains a positive culture while scaling its production, global sales, and new product development.
  • Robert Coward. Mr. Coward recently joined Bonumose as Vice President for Finance & Accounting. Mr. Coward was with Xerox (NASDAQ: XRX), an S&P 400 company, for 28 years. Throughout his career Mr. Coward has held increasingly senior leadership roles in finance as well as operations.
  • Ross Bartels. Mr. Bartels, a recent graduate of the University of Virginia School of Law, joined Bonumose as its first in-house legal counsel. Mr. Bartels areas of focus for Bonumose include intellectual property protection, regulatory and administrative law, and general legal matters. Bonumose has over 50 granted patents globally and many more patent applications pending, and also is engaging with food ingredient regulatory bodies globally.

Bonumose is based in Albemarle County, Virginia, and was selected as a Technology Pioneer by the World Economic Forum.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and